New York State Department of Health grants approval to Counsyl for Prelude Prenatal Screen
Genetic screening and counseling services company, Counsyl sought approval from the New York State Department of Health to provide Prelude Prenatal Screen in New York therefore intimating patients about their baby’s development details.
The benefits of Counsyl Prelude Prenatal Screen are primarily for ascertaining aa chromosomal condition like Down Syndrome. It is basically a non-invasive prenatal screen (NIPS) performed as early as the tenth week of pregnancy that uses cell-free DNA from maternal blood. After a sample of blood is taken, Counsyl uses whole-genome sequencing and combines custom algorithms and bioinformatics with expert analysis. Prelude relatively has a low failure rate of 0.1% hence alleviating the necessity for chorionic villus sampling (CVS) or amniocentesis.
Dr. James Goldberg, chief medical officer at Counsyl. “New York has one of the most rigorous assessments for genetic screening and this endorsement gives credence to the quality and reliability of Counsyl’s technology.”
Counsyl has championed advances in genetic screening for women and their families and has screened more than 850,000 patients, served more than 17,000 health care providers and provided more than 60,000 genetic counseling sessions till date.
Counsyl’s proprietary products include :
- Counsyl Foresight Carrier Screen
- Counsyl Prelude Prenatal Screen
- Counsyl Relaint Cancer Screen
- Counsyl Complete